• 23 April 2020

    Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today reported cash and cash equivalents of €5.6 million as of March 31, 2020. This amount does not include the French research tax credit of €0.9 million which was received by the Company in April 2020. The existing cash and cash equivalents provide cash runway to end of February 2021. 

  • 19 March 2020

    Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces its financial results for the year ended 31 December 2019, and provides a business update and an outlook for the remainder of 2020.

  • 12 March 2020

    Sonendo®, Inc., a dental technology company developing and commercializing products to save teeth through Sound Science®, announced today the appointment of Amit Agarwal as Vice President of Marketing. Mr. Agarwal will assume the responsibility for Sonendo's marketing organization, including product portfolio management, commercialization, professional education, training and communications.

  • 12 March 2020

    X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2019.

  • 4 March 2020

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, reported today financial results for the fourth quarter and year ended December 31, 2019 and provided an update on operational initiatives.